-
公开(公告)号：KR1020070087753A
公开(公告)日：2007-08-29
申请号：KR1020050098640
申请日：2005-10-19
Applicant: 신풍제약주식회사
IPC: C07D211/90
Abstract: A method for preparing anhydrous hydrochloride salt of 1,4-dihydropyridine derivative is provided to obtain the desired product with high purity and high yield under mild and safe conditions using an activated intermediate. The method comprises the steps of: (a) reacting a compound of the formula(III) with a compound of the formula(IV) to prepare a compound of the formula(V); (b) reacting the compound of the formula(V) with a compound of the formula(II) to prepare an activated intermediate of a compound of the formula(VII) and/or the formula(VI); (c) reacting the intermediate with a compound of the formula(VIII) to prepare a compound of the formula(I); and (d) treating the compound with hydrochloric acid and then crystallizing it.
Abstract translation: 提供了制备1,4-二氢吡啶衍生物的无水盐酸盐的方法，使用活化的中间体在温和和安全条件下获得高纯度和高产率的所需产物。 该方法包括以下步骤：（a）使式（III）的化合物与式（Ⅳ）的化合物反应制备式（Ⅴ）化合物; （b）使式（V）的化合物与式（II）的化合物反应以制备式（VII）和/或式（VI）的化合物的活化中间体; （c）使中间体与式（Ⅷ）化合物反应制备式（Ⅰ）化合物; 和（d）用盐酸处理化合物，然后使其结晶。
-
公开(公告)号：KR100679166B1
公开(公告)日：2007-02-06
申请号：KR1020050093008
申请日：2005-10-04
Applicant: 신풍제약주식회사
IPC: A61K9/16 , A61K31/403
Abstract: A pharmaceutical composition comprising ramipril is provided to show excellent stability against mechanical stress by granulation with mannitol solution. And a method for preparing a pharmaceutical formulation comprising stabilized ramipril is provided to simplify the preparation process, thereby obtaining the ramipril containing formulation within short period of time and maintaining the stability of the formulation for a long time. The pharmaceutical composition is characterized in that ramipril as an active ingredient is granulated with mannitol solution. In the composition, the weight ratio of the ramipril to mannitol is 1:0.25-1. The pharmaceutical oral formulation comprises the pharmaceutical composition and a pharmaceutically acceptable excipient.
Abstract translation: 提供包含雷米普利的药物组合物，以通过用甘露糖醇溶液造粒显示优异的抗机械应激稳定性。 并且提供了一种用于制备包含稳定的雷米普利的药物制剂的方法，以简化制备过程，从而在短时间内获得含有雷米普利的制剂并长时间保持制剂的稳定性。 该药物组合物的特征在于作为活性成分的雷米普利与甘露醇溶液一起造粒。 在该组合物中，雷米普利与甘露糖醇的重量比为1:0.25-1。 药物口服制剂包含药物组合物和药学上可接受的赋形剂。
-
23.发明公开
公开(公告)号：KR1020030059961A
公开(公告)日：2003-07-12
申请号：KR1020020000516
申请日：2002-01-04
Applicant: 신풍제약주식회사
IPC: C07D215/14
Abstract: PURPOSE: Provided is (±)-2-(4-chlorobenzoylamino)-3-(2(1H)-quinolinone-4-mono)propionic acid which is prepared through simplified processing steps at high yield and high purity. CONSTITUTION: 4-halomethyl-2(1H)-quinolinone(formula III) reacts with dialkyl 4-chlorobenzoylamino malonate(formula IV) in the presence of an inorganic base in an alcoholic solvent to prepare alkyl 2-(4-chlorobenzoylamino)-2-(alkoxycarbonyl)-3-(2(1H)-quinolinone-4-mono)propionate(formula II) as an intermediate. It selectively suffers decarboxylation and hydrolysis using an acids mixture wherein acetic acid is mixed with other acids in a volume ratio of 1:0.3-10.2, thereby preparing the (±)-2-(4-chlorobenzoylamino)-3-(2(1H)-quinolinone-4-mono)propionic acid(formula I). In the formulas, R is C1-6 alkyl group, and X1 is halogen.
Abstract translation: 目的：提供（±）-2-（4-氯苯甲酰氨基）-3-（2（1H） - 喹啉酮-4-单）丙酸，其通过简单的加工步骤以高产率和高纯度制备。 构成：4-卤代甲基-2（1H） - 喹啉酮（式III）在无水碱存在下在醇溶剂中与4-氯苯甲酰基氨基丙二酸二烷基酯（式Ⅳ）反应制备2-（4-氯苯甲酰氨基）-2 - （烷氧基羰基）-3-（2（1H） - 喹啉酮-4-单）丙酸酯（式II）作为中间体。 它选择性地使用酸混合物进行脱羧和水解，其中乙酸与体积比为1:0.3-10.2的其它酸混合，从而制备（±）-2-（4-氯苯甲酰氨基）-3-（2（1H， ） - 喹啉酮-4-单）丙酸（式I）。 式中，R为C1-6烷基，X1为卤素。
-
公开(公告)号：KR1020030035266A
公开(公告)日：2003-05-09
申请号：KR1020010067249
申请日：2001-10-30
IPC: C12N15/85
CPC classification number: C12N15/85 , C07K14/505 , C12N5/0682 , C12P21/02
Abstract: PURPOSE: A recombinant vector for animal cells and a method for producing erythropoietin using the same vector are provided, thereby the erythropoietin can be mass-produced and the erythropoietin produced has the same physiological activity as natural erythropoietin. CONSTITUTION: The recombinant vector for animal cells comprises a promoter of cytomegalovirus containing a binding sequence of a mutated methylated DNA binding protein wherein a low affinity binding portion is substituted by a high affinity binding portion, dhfr operably linked to the cytomegalovirus promoter and replication origin. The expression vector for animal cell to mass-produce erythropoietin comprises a promoter of cytomegalovirus containing a binding sequence of modified methylated DNA binding protein wherein a low affinity binding portion is substituted by a high affinity binding portion, dhfr operably linked to the cytomegalovirus promoter, replication origin, a gene encoding erythropoietin, and a promoter operably linked to the erythropoietin gene which is operated in eukaryotic cells.
Abstract translation: 目的：提供用于动物细胞的重组载体和使用相同载体产生促红细胞生成素的方法，从而大量产生红细胞生成素，并且所产生的促红细胞生成素具有与天然促红细胞生成素相同的生理活性。 构成：用于动物细胞的重组载体包含巨细胞病毒的启动子，其含有突变的甲基化DNA结合蛋白的结合序列，其中低亲和力结合部分被高亲和力结合部分取代，dhfr可操作地连接到巨细胞病毒启动子和复制起点。 用于大规模生产促红细胞生成素的动物细胞的表达载体包含含有修饰的甲基化DNA结合蛋白的结合序列的巨细胞病毒的启动子，其中低亲和力结合部分被高亲和力结合部分取代，dhfr可操作地连接到巨细胞病毒启动子，复制 起源，编码促红细胞生成素的基因，以及与在真核细胞中操作的红细胞生成素基因可操作地连接的启动子。
-
公开(公告)号：KR100354271B1
公开(公告)日：2002-09-28
申请号：KR1020000005071
申请日：2000-02-02
Applicant: 신풍제약주식회사
IPC: C07C229/00
Abstract: 본 발명은 해열제, 골관절염 및 류마티스관절염 등의 관절질환과 각종 통증에 우수한 치료 효과를 나타내는 소염진통제로 널리 알려져 있는 화학식 1의 화합물[관용명:아세클로페낙(Aceclofenac)]의 신규 제조방법 및 그 제조 과정에서 중간체로 사용되는 화학식 2의 화합물 및 그의 제조방법에 관한 것이다:
상기식에서, R
1 은 C
1-4 알킬렌이고 R
2 는 C
1-4 알킬이다.
본 발명은 매우 저렴하고 사용이 편리한 산(acid)을 사용하여 선택적으로 가수분해시킴으로써 고수율 및 고순도의 화학식 1의 아세클로페낙을 간편하게 제조할 수 있다.-
Patent Agency Ranking
公开(公告)号：KR100233873B1
公开(公告)日：2000-02-01
申请号：KR1019970047833
申请日：1997-09-19
Applicant: 신풍제약주식회사
Abstract: 본 발명은 구인(Lumbricus rubellus)으로부터 추출되는 단백질분해 효소인 롬브로키나제를 함유하는 혈관근이완제 조성물에 관한 것이다. 더욱 구체적으로, 본 발명은 구인으로부터 일련의 과정을 거쳐 분리되는 롬브로키나제 활성분획을 활성성분으로 함유하는 이완제 조성물에 관한 것이다.
-
公开(公告)号：KR1020000003837A
公开(公告)日：2000-01-25
申请号：KR1019980025129
申请日：1998-06-29
Applicant: 신풍제약주식회사
IPC: A61K31/14
CPC classification number: A61K31/661 , A61K45/06 , A61K2300/00 , Y10S514/885
Abstract: PURPOSE: An immune enhancer is provided to be used as an antibiotic and an anti-cancer medicine separately or mixed with another ingredient. CONSTITUTION: An immune enhancer containing a lombricine as an effective ingredient activates an immuno-cell of an organism for having an effect of enhancing an immune of the organism. The immune enhancer may be used as an antibiotic and an anti-cancer medicine separately or by mixed with other antibiotic or anti-cancer medicine for minimizing a virulence and maximizing an effect.
Abstract translation: 目的：提供免疫增强剂，用作抗生素和抗癌药物，或与其他成分混合使用。 构成：含有作为有效成分的洛米奇的免疫增强剂激活生物体的免疫细胞，以增强生物体的免疫作用。 免疫增强剂可以分别用作抗生素和抗癌药物，也可以与其它抗生素或抗癌药混合使用，以使毒性最小化并使效果最大化。
-
公开(公告)号：KR100129686B1
公开(公告)日：1998-04-04
申请号：KR1019940007203
申请日：1994-04-06
Applicant: 신풍제약주식회사
IPC: C07H19/20
Abstract: The present invention provides 1-beta-D-arobino furanocyl cytocin-5'-stearylphosphate mono sodium salt, which is used as cytocine arabinocide derivatives having great usefulness as anticancer drugs. 1-beta-D-arabinofuranocyl cytocin-5'-stearylphosphate or its amonium salt dissolved in halogenated hydrogen chlorides such as chloroform, dichloromethane or alcohol is passed through cationic ion exchange resin to produce 1-beta-D-arabinofuranocyl cytocin-5'-stearyl phosphate mono ammonium salt.
Abstract translation: 本发明提供了作为抗癌药物具有很大用途的1-β-D-arobino呋喃果糖胞嘧啶-5'-硬脂酰磷酸单钠盐，其用作细胞碱阿拉伯糖苷衍生物。 溶解在卤代氯化物如氯仿，二氯甲烷或醇中的1-β-D-阿拉伯呋喃果糖胞嘧啶-5'-硬脂基磷酸酯或其二铵盐通过阳离子离子交换树脂以产生1-β-D-阿拉伯呋喃果糖基细胞质-5'- 硬脂基磷酸酯单铵盐。
-
公开(公告)号：KR1019960013367A
公开(公告)日：1996-05-22
申请号：KR1019940027450
申请日：1994-10-26
Applicant: 신풍제약주식회사
IPC: A61K9/48 , A61K31/505
Abstract: 본 발명은 경구용 백혈병 치료제로서 유용한 시티라빈 옥포스페이트를 함유하는 경질컵셀제에 관한 것이다. 더욱 구체적으로 본 발명은(1) 시타라빈 옥포스페이트, (2) 나트륨라우릴설페이트 및 나트륨도큐세이트 중에서 선택된 계면활성제, (3) 붕해제인 콜로이드성 이산화규소, (4) 알칼리화제인 나트륨시트레이트를 함유함을 특징으로 하는 경질캅셀제에 관한 것이다. 본 발명의 경질 캅셀제는 상기한 바와 같은 특정의 성분들의 조합으로 이루어져 있기 때문에 산성용액중에서도 탁월한 용출성, 붕해성 및 안정성을 제공한다.
-
公开(公告)号：KR1019960009999A
公开(公告)日：1996-04-20
申请号：KR1019940025054
申请日：1994-09-30
Applicant: 신풍제약주식회사
IPC: A61K9/30 , A61K31/415
-
-
-
-
-
-
-
-
-
Search Results
84
records
(took 0.021 seconds)
